Nicox
Nicox is a France-based ophthalmology company that discovers, develops and commercializes novel ophthalmic therapeutics for the treatment of eye diseases.
Business Model:
Revenue: $9.7M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Nicox Information
Geographic Data
Address: 2405 route des Dolines – CS 10313
City: Valbonne
State: provence-alpes-côte-d'azur
Zip: 06560
Country: FR
Financial Info
Stage:
post ipo equity
Raised Last:
$10M
Raised Total:$64M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Nicox is a France-based ophthalmology company that discovers, develops and commercializes novel ophthalmic therapeutics for the treatment of eye diseases.
Contact Phone:
Contact Email:
Nicox went public on 12/29/2000 on the PA
Listed Exchange:
PA
IPO Date:
12/29/2000
Ticker Symbol:
COX
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2019 | Post-IPO Debt | 1 | $22.8M |
Kreos Capital Kreos Capital Kreos Capital Kreos Capital |
12/2019 | Debt | $8.9M |
Kreos Capital |
8/2017 | Equity | $31M | 11/2022 | Post-IPO Equity | $10.3M | 11/2022 | Post-IPO Equity | $10.4M | 11/2019 | Private Placement | $13.8M |
HBM Healthcare Investments |
12/2021 | Post-IPO Equity | $16.9M | 11/2009 | Post-IPO Equity | $149M |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 9/2014 | Doliage | |
| 7/2014 | Aciex Therapeutics | |
| 12/2013 | EuPharmed |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
